Budesonide [Entocort EC ]
Budesonide (Entocort EC) received FDA approval in 2001, and represents a new class of corticosteroids: nonsystemic steroids. This type of drug is rapidly metabolized and quickly cleared from the bloodstream. As a result, it substantially reduces the unpleasant side effects often associated with traditional steroids. Budesonide is approved for treatment of mild to moderate, active Crohn's disease involving the small intestine (ileum) and the first part of the large intestine (ascending colon). Studies show budesonide to be as effective as traditional steroids, but with far fewer unpleasant side effects. A recent study compared budesonide to mesalamine. The study showed that 69% of patients with mild to moderate, active Crohn's disease taking budesonide showed significant clinical improvement after eight weeks, compared to 45% of the patients taking mesalamine.
On behalf of learning, and use as teaching tools for those of us who need to
know about our disease, I have tried to supply you with as much information as
I could find on all of the drugs, treatments and disorders associated with
Inflammatory Bowel Diseases. I have tried to blend all facts supported by research
and also from personal experiences of other IBD sufferers into one readable webpage, and any and all information presented here is not entirely
from one source. Most information contained within these pages is found in the public domain.
At times you may find information used from another site, and as with all copyrighted materials you may find on these pages, I claim fair use under sections 107 through 118 of the Copyright Act (title 17, U.S. Code). Click here for more info
|
- Achieve health, fitness, relaxation, and balance with
Wai Lana Yoga
|
My Story 
